淋巴瘤患者血浆和PBMC EBV定量测定的对比研究

目的 比较分析淋巴瘤患者血浆和外周血单个核细胞(PBMC) EBV-DNA的阳性率及病毒载量.方法 采用荧光定量PCR法,对56例淋巴瘤患者(霍奇金淋巴瘤13例,非霍奇金淋巴瘤43例)血浆和PBMC EBV-DNA进行定量测定,比较分析两种样本的EB病毒阳性率及EBV载量的差异.结果 淋巴瘤患者血浆EBV-DNA阳性率(26.8％)与PBMCEBV-DNA阳性率(32.1％)之间差异无统计学意义(P＞0.05);EB阳性淋巴瘤患者血浆与PBMC的EBV栽量之间差异也无统计学意义(P＞0.05).结论 荧光定量PCR检测血浆EBV-DNA具有较好的特异性和敏感性,血浆EBV-DNA定量可以代替PBMC EBV-DNA定量作为监测EBV阳性淋巴瘤疗效的一个生物标志.     

实时荧光定量PCR在EB病毒DNA检测中的应用

目的探讨实时荧光定量PCR技术在检测患者外周血单个核细胞(PBMC)中EB病毒(EBV)DNA定量的临床应用,比较实时荧光定量PCR在检测血浆和PBMC中EBV DNA含量的差别,并研究EBV阳性患者的病种分布特点。方法应用罗氏Light Cycler荧光定量PCR仪检测375例患者PBMC中EBV DNA含量,所有阳性患者均用血浆进行复查,比较其差别,并回顾性分析患者临床特点。结果检测PBMC中EB阳性标本35例,阳性率为9.3%。阳性患者中鼻炎13例,鼻咽癌4例,鼻息肉4例,肺炎7例,急性淋巴细胞性白血病1例,传染性单核细胞增多症6例。取阳性标本检测其血浆游离EB DNA,33例阳性,其拷贝数低于相应标本中PBMC中的拷贝数。结论实时荧光定量PCR技术检测PBMC和血浆中EB DNA准确,快速,在确诊EBV感染相关性疾病中具有重要的作用,且检测PBMC中EB DNA可能更优于检测血浆中EB DNA。     

不同样本类型对EBV DNA检测结果的影响

目的探讨不同样本类型[外周血单个核细胞(PBMC)和血浆]对EB病毒(EBV)DNA检测结果的影响。方法采用实时荧光定量聚合酶链反应(PCR)同时检测2 694例不同疾病患者的PBMC及血浆中的EBV DNA,分析不同疾病患者不同样本类型之间EBV DNA阳性率的差异。结果在2 694例检测EBV DNA的患者中,PBMC和血浆均阳性的有131例(4.86%),血浆阴性而PBMC阳性的有1 045例(38.79%),血浆阳性而PBMC阴性的有3例(0.11%)。一致性检验结果显示,2种样本检测结果的一致性差(Kappa0.4)。84例鼻咽癌患者中有24例(28.57%)PBMC EBV DNA阳性,血浆EBV DNA均为阴性。119例霍奇金淋巴瘤患者中有45例(37.82%)PBMC EBV DNA阳性,有39例(32.77%)血浆EBV DNA阴性而PBMC EBV DNA阳性。466例非霍奇金淋巴瘤患者中有193例(41.42%)PBMC EBV DNA阳性,有169例(36.27%)血浆EBV DNA阴性而PBMC EBV DNA阳性。不同疾病患者PBMC EBV DNA拷贝数均高于血浆(P0.001)。结论 PBMC EBV DNA阳性率及拷贝数均高于血浆,建议结合疾病类型选用合适的样本类型。     

孝感地区传染性单核细胞增多症患儿EBV抗体、 DNA检测结果及社区居民流行病学分析

目的 分析孝感地区传染性单核细胞增多症(IM)患儿EB病毒(EBV)抗体及DNA检测结果,并分析该地区社区居民EBV抗体携带的流行病学特点。方法 选取2016年12月至2020年12月在该院住院的IM患儿120例为病例组,选取同期于该院体检的儿童124例为对照组。从该院体检者中选取具备EBV抗体及DNA检测结果的1 522例孝感地区社区居民作为流行病学调查对象。用酶联免疫吸附试验检测EBV抗体,采用实时荧光定量PCR检测血浆及外周血单个核细胞(PBMC)中EBV DNA水平。结果 病例组EBV DNA、衣壳抗原(VCA) IgA、VCA IgM、核抗原(NA) IgA、早期抗原(EA) IgA阳性率均高于对照组,VCA IgG、NA IgG阳性率均低于对照组,差异有统计学意义(P<0.05)。各年龄段社区居民VCA IgA、NA IgA、EA IgA阳性率均较低,NA IgG和VCA IgG在≥1岁居民中阳性率随着年龄增长有逐渐增高趋势,在≥60岁居民中NA IgG、VCA IgG阳性率均达100%。120例IM患儿中,有72例患儿同时采集PBMC及血浆标本进行了EBV DNA检...     

血浆EBV—DNA检测对鼻咽癌的诊断价值的探讨

目的探讨血浆EBV—DNA定量测定对鼻咽癌的诊断价值。方法收集2008年5月-2010年5月在本院确诊的初诊鼻咽癌患者52例以及同期住院其它肿瘤患者127例、健康对照者50例,分别采集血浆标本,应用荧光定量PCR方法检测EB病毒DNA含量,比较鼻咽癌患者、其它肿瘤患者、健康对照组血浆EBV—DNA拷贝含量水平的差异。结果鼻咽癌患者血浆EBV—DNA阳性率和复制量均高于其它肿瘤患者和健康对照者。各组阳性率和中位浓度的比较均有统计学差异。结论血浆EBV—DNA定量检测是一种敏感而可靠的实验方法,对鼻咽癌的诊断具有重要价值。     

淋巴细胞及血浆EB病毒DNA在EBV感染相关疾病中表达的研究

目的探讨外周血淋巴细胞和血浆中EB病毒DNA(EBV DNA)在EB病毒感染相关疾病中表达的差异。方法收集112例疑似EB病毒感染相关疾病患者的全血样本,其中鼻咽癌14例,传染性单核细胞增多症(传单)16例,淋巴瘤22例,自身免疫性疾病23例,上呼吸道感染26例,肝功能异常11例,采用荧光定量PCR方法检测同一份样本淋巴细胞和血浆中EBV DNA的含量。结果检测112例患者外周血淋巴细胞和血浆中的EBV DNA,其总的阳性率分别为83.0%(93/112),27.7%(31/112),差异具有统计学意义(卡方值χ~2=60.02,P0.01);14例鼻咽癌患者外周血淋巴细胞和血浆EBV DNA的阳性率及其含量差异均无统计学意义(χ~2=2.25,t=-1.04,均P0.05);而传染性单核细胞增多症、淋巴瘤、自身免疫性疾病、上呼吸道感染和肝功能异常患者血浆EBV DNA阳性率及其含量均明显低于外周血淋巴细胞,差异具有统计学意义(χ~2=4.17~15.06,均P0.05;t=3.94~10.45,均P0.01)。结论荧光定量PCR检测非鼻咽癌患者的外周血淋巴细胞的EBV DNA可能优于检测血浆的EBV DNA;检测鼻咽癌患者外周血淋巴细胞和血浆EBV DNA无明显差异,可根据临床情况,选择合适的标本进行检测。     

EBV—DNA检测在儿童EB病毒感染中的临床意义

目的探讨荧光定量PCR检测EB病毒（EBV）对诊断和治疗EBV感染的临床意义。方法应用荧光定量聚合酶链反应病毒核酸扩增方法,对儿科2010—06～2012—06以发热为主诉的患儿205例,检测外周血EB病毒DNA栽量,结合常规外周血及异型淋巴细胞检查,对照首发临床表现,分析荧光定量PCR检测发热患儿感染EBV的临床价值。结果205例发热患儿中,外周血EBV—DNA阳性42例,阳性率20．5％。荧光定量PCR检测EB病毒能早期反映EBV感染。结论荧先定量PCR检测EBv—DNA有助于早期诊断EBV感染,能减少诊疗的盲目性,对临床有一定指导意义。     

43例多发性骨髓瘤骨髓EB病毒DNA检测

目的用荧光定量PCR方法检测急性白血病（AL）与多发性骨髓瘤患者（MN）骨髓中EBV—DNA含量,并探讨其临床意义。方法采用荧光定量PCR技术检测38例急性白血病与43倒多发性骨髓瘤患者EBV感染情况,同时检测了32例对照组小细胞低色素性贫血和巨幼细胞性贫血患者骨髓EBV—DNA含量。结果多发性骨髓瘤患者EBV感染率为58．1％,急性白血病组EBV感染率为8．0％,对照组EBV感染率6．2％。AL组与对照组EBV—DNA阳性率无显著性差异（P〉0．05）,MM组与对照EBV—DNA阳性率有显著性差异（P〈0．01）,MM组与AL组EBV—DNA阳性率有显著性差异（P〈0．01）。结论AL患者的发病与EB病毒感染关系不大,MM患者的发病与EB病毒感染有关;应用荧光定量PCR方法对MM患者骨髓中,EBV—DNA舍量进行检测,对于揭示MM的发病与EBV感染之间的相关性提供了敏感可靠的检测方法。     

快速诊断结核杆菌感染的PCR方法的实验室应用

[目的]寻找一种即能提高检出的阳性率，又能减少污染环节而导致假阳性，取材方便，操作简单，便于推广的临床标本进行PCR扩增，来进行结核病的实验室快速诊断。[方法]对经X-线、胸片、痰抗酸染色、痰BLL-MGIT快速培养及临床诊断确诊为结核病例40例的痰、全血、外周血单个核细胞进行TB-Ab、PCR的检测比较。[结果]痰液中的结核杆菌-DNA的PCR检出率高达70％，而同一患者外周血分离单个核细胞的阳性率仅为40％。同一血样中TB-Ab与全血PCR方法扩增全血中所有的模版DNA，两方法之间具有显著性差异。全血PCR与外周血单个核细胞PCR比较，二者的阳性率具有显著性差异（P=0．001〈0．01），以全血细胞PCR检测阳性率最高。结核杆菌感染者红细胞粘附功能明显增加，与正常对照组比较县有显著性差异。[结论]检测结核病患者全血细胞TB的PCR实验方法可能为结核杆菌感染的早期、有效的实验室指标。     

肺癌患者血浆及外周血单个核细胞Lunx mRNA检测的临床意义

目的检测肺癌患者血浆及外周血单个核细胞肺特异性X基因(Lunx)mRNA,探讨两者对肺癌辅助诊断的临床意义。方法采用荧光定量聚合酶链反应(PCR)检测肺癌患者、肺良性疾病患者、肺外肿瘤患者及健康人血浆及外周血单个核细胞Lunx mRNA。结果肺癌组患者血浆Lunx mRNA阳性率显著高于肺良性疾病组(χ2=113.10,P<0.01)、肺外肿瘤组(χ2=125.34,P<0.01)和健康组(χ2=100.33,P<0.01);Ⅲ～Ⅳ期肺癌患者血浆Lunx mRNA阳性率高于Ⅰ、Ⅱ期肺癌患者(χ2=7.07,P<0.05)。肺癌组患者外周血单个核细胞LunxmRNA阳性率显著高于肺良性疾病组(χ2=32.79,P<0.01)、肺外肿瘤组(χ2=44.44,P<0.01)和健康组(χ2=44.44,P<0.01);Ⅲ～Ⅳ期肺癌患者外周血单个核细胞Lunx mRNA阳性率显著高于Ⅰ、Ⅱ期肺癌患者(χ2=24.52,P<0.01)。血浆Lunx mRNA检测对肺癌辅助诊断的敏感性高于单个核细胞检测的敏感性(χ2=36.46,P<0.01),血浆检测的阴性预测值高于外周血单个核细胞检测的阴性预测值(χ2=16.37,P<0.01)。结论血浆与外周血单个核细胞Lunx mRNA检测均可用于肺癌的辅助诊断,前者敏感性较后者高。     

Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms

Reliable real-time quantitative PCR assays to measure Epstein-Barr virus (EBV) DNA load (EBV) are useful for monitoring EBV-associated diseases. We evaluated a new commercial kit, EBV R-gene Quantification kit (Argene, Varilhes, France) to quantify EBV DNA load in whole blood. Assay performance was assessed with two PCR platforms (LightCycler 2.0 and SmartCycler 2.0) and three commercial DNA extraction methods. The assay was compared with our in-house real-time EBV PCR using samples from the Quality Control for Molecular Diagnostics 2006 EBV proficiency program and using 167 whole-blood specimens from individuals with infectious mononucleosis, from transplanted or HIV-infected patients, and from EBV-seropositive healthy carriers. The EBV R-gene assay was sensitive to 500 copies of EBV DNA per milliliter of whole blood with the two PCR platforms and the three extraction methods and was linear across 4 orders of magnitude. Intra- and interassay coefficients of variations were less than 20%. Nine of 10 samples tested with the EBV R-gene were in agreement with the expected qualitative results of the Quality Control for Molecular Diagnostics 2006 EBV proficiency program, and 7 of 10 samples were within +/-0.5 log units of the expected quantitative values, with discrepant results mostly observed for low viral load (ie, <1000 copies/ml). In the clinical specimens, the correlation between the R-gene assay and the in-house PCR was high (r=0.92). In conclusion, the EBV R-gene assay accurately assesses the EBV DNA load in whole blood of patients with various forms of EBV infections.     

Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting

Epstein-Barr virus (EBV) is associated with a wide range of benign and malignant diseases, including infectious mononucleosis, lymphoma, posttransplant lymphoproliferative disorder, and nasopharyngeal carcinoma. Measurement of EBV viral load in plasma is increasingly used for rapid assessment of disease status. We evaluated the performance characteristics of an EBV polymerase chain reaction assay that uses commercial reagents and instruments from Roche Diagnostics (Indianapolis, IN). DNA was extracted from plasma using a MagNaPure instrument, and viral load was measured by real-time polymerase chain reaction on a LightCycler. Analyte-specific reagents included primers and hybridization probes targeting the EBV LMP2 gene and a spiked control sequence. Accuracy and reproducibility were established using DNA from three cell lines. The assay was sensitive to approximately 750 copies of EBV DNA per milliliter of plasma and was linear across at least four orders of magnitude. The assay detected EBV DNA in three of five samples from nasopharyngeal carcinoma patients, seven of nine infectious mononucleosis samples, and 34/34 samples from immunosuppressed patients with clinically significant EBV-related disease, whereas EBV DNA was undetectable in plasma from 21 individuals without EBV-related disease. In conclusion, this LightCycler EBV assay is rapid, sensitive, and linear for quantifying EBV viral load. The assay appears to be useful for measuring clinically significant EBV levels in immunodeficient patients.     

Comparison of QIAsymphony automated and QIAamp manual DNA extraction systems for measuring Epstein-Barr virus DNA load in whole blood using real-time PCR

Automated and manual extraction systems have been used with real-time PCR for quantification of Epstein-Barr virus [human herpesvirus 4 (HHV-4)] DNA in whole blood, but few studies have evaluated relative performances. In the present study, the automated QIAsymphony and manual QIAamp extraction systems (Qiagen, Valencia, CA) were assessed using paired aliquots derived from clinical whole-blood specimens and an in-house, real-time PCR assay. The detection limits using the QIAsymphony and QIAamp systems were similar (270 and 560 copies/mL, respectively). For samples estimated as having ≥10,000 copies/mL, the intrarun and interrun variations were significantly lower using QIAsymphony (10.0% and 6.8%, respectively), compared with QIAamp (18.6% and 15.2%, respectively); for samples having ≤1000 copies/mL, the two variations ranged from 27.9% to 43.9% and were not significantly different between the two systems. Among 68 paired clinical samples, 48 pairs yielded viral loads ≥1000 copies/mL under both extraction systems. Although the logarithmic linear correlation from these positive samples was high (r(2) = 0.957), the values obtained using QIAsymphony were on average 0.2 log copies/mL higher than those obtained using QIAamp. Thus, the QIAsymphony and QIAamp systems provide similar EBV DNA load values in whole blood.     

Comparison of 2 highly automated nucleic acid extraction systems for quantitation of human cytomegalovirus in whole blood

The aim of the study was to evaluate analytical performances of the COBAS Ampliprep and to compare extraction from whole blood on the COBAS Ampliprep and on the MagNA Pure instruments (Roche Diagnostics, Mannheim, Germany) for quantifying human cytomegalovirus (HCMV) DNA with real-time polymerase chain reaction (PCR). The limit of detection using the COBAS Ampliprep was 10 copies/run (150 copies/mL, i.e., 2.20 log(10) copies/mL). Quantitation of HCMV-DNA was linear from 3.0 to 6.0 log(10) copies/mL. The intra-assay variations ranged from 11.1 % to 0.4 % and interassay variation was 11.3 %. A total of 107 samples were tested using both extraction systems. Only 3 samples gave discrepant results. Correlation between HCMV virus loads was good (r = 0.73) (P < 0.001). Mean virus load was lower (-0.49 log(10) copies/mL) with COBAS Ampliprep than with MagNA Pure extraction system. Both MagNA Pure and COBAS Ampliprep provide reliable and high-throughput platforms for real-time PCR HCMV quantitation of DNA extracted from whole blood.     

淋巴组织增生性疾病患者外周血EBV DNA定量检测临床意义的研究进展

目前发现爱泼斯坦巴尔病毒(Epstein-Barr virus,EBV)与多种淋巴组织增生性疾病的关系越来越密切,主要包括EBV相关淋巴瘤、EBV阳性淋巴组织增殖性疾病(EBV+LPD)以及传染性单核细胞增多症(infectious mononucleosis,IM)等,以往研究认为EBV+LPD及IM的外周血EBV ...     

基于ddPCR技术分析EB病毒载量特征及与qPCR技术的比较研究

目的解决临床工作中应用实时荧光定量PCR(qPCR)方法检测EB病毒(EBV)载量与临床诊断不符的问题,探讨微滴式数字PCR(ddPCR)和qPCR方法检测EBV载量的能力并为临床提供可能的解决方案。方法收集510例疑似EBV感染相关疾病患者血浆标本,采用ddPCR和qPCR两种方法测定同一血浆标本的EBV-DNA载量。结果 EBV感染人群中,EBV-DNA载量较其他地区低,载量中位数仅360copies/mL,其中初诊未治鼻咽癌患者中位病毒载量为4 590copies/mL,治疗后鼻咽癌患者中位病毒载量下降为430copies/mL,免疫力低下者中位病毒载量为130copies/mL,而淋巴瘤患者中位病毒载量为840copies/mL;qPCR检测EBV感染以400copies/mL为界值,高于400copies/mL时,ddPCR与qPCR的EBV-DNA测定水平值呈中度相关(r=0.533,P<0.05),低于400copies/mL时,ddPCR与qPCR的EBV-DNA测定水平值呈弱相关(r=0.299 5,P<0.05);以ddPCR为标准,qPCR检测EBV-DNA的灵敏度仅为0.317,以ddPCR检测结果为标准,构建qPCR的受试者工作特征曲线下面积为0.871,此时临界值(qPCR)为10copies/mL,灵敏度为0.824,特异度为0.780。结论采用ddPCR方法或优化qPCR的临界值去检测EBV-DNA载量更能为临床诊断EBV感染提供有利支持。     

儿童传染性单核细胞增多症临床特征分析

目的探讨儿童传染性单核细胞增多症（IM）的临床特点。方法回顾性分析2005年8月-2009年8月收治的151例IM患儿的症状、体征、实验室检查及治疗效果。结果 IM临床表现以发热、咽峡炎、肝脾和淋巴结肿大最常见,鼻塞、眼睑浮肿也是重要体征。外周血出现异型淋巴细胞及EBV-IgM抗体检测可帮助确诊。更昔洛韦治疗IM效果确切。结论应重视IM临床特点,有助于早期诊断并提高确诊率,应用更昔洛韦治疗值得推广。     

间充质干细胞调控趋化因子配体2对系统性红斑狼疮作用的机制探讨

目的:探讨趋化因子配体2[chemokine(C-C motif)ligand 2,CCL2]在间充质干细胞(mesenchymal stem cells,MSCs)移植治疗系统性红斑狼疮(systemic lupus erythematosus,SLE)中的作用。方法:采用酶联免疫吸附试验检测SLE患者及正常对照者的血清、尿液及骨髓MSCs培养上清中的CCL2及白细胞介素(interleukin,IL)-17的表达水平,并采用流式细胞术检测外周血单个核细胞(peripheral blood mononuclear cells,PBMCs)中Th17-CD4+IL-17+的百分率及其表面CCR2的表达。将18只雌性MRL/lpr SLE小鼠随机分为SLE小鼠组(n=6)(未治疗组)、脐带MSCs移植联合CCL2中和抗体治疗SLE小鼠组(n=6)及脐带MSCs移植联合同型对照IgG2B治疗SLE小鼠组(n=6),另选6只同周龄雌性C57BL/6小鼠作为健康阴性对照组。采用酶联免疫吸附试验检测各组血清CCL2及IL-17的水平,流式细胞术检测各组PBMCs中CD4+CCR2+IL-17+细胞百分率。结果:SLE患者血清[(839.0±160.5)pg/mL]、尿液[(881.8±162.7)pg/mL]及骨髓MSCs培养上清[(22 935±2 304)pg/mL]的CCL2含量均显著高于正常对照者[(433.0±31.0)pg/mL、(222.7±52.8)pg/mL、(8 394±5 125)pg/mL];SLE患者PBMCs中CD4+CCR2+IL-17+细胞百分率较正常对照者显著升高(P<0.01)。脐带MSCs移植联合CCL2中和抗体治疗SLE小鼠组血清CCL2浓度显著低于未治疗组,PBMCs中CD4+T细胞亚群IL-17、CCR2表达较未治疗组显著降低。结论:MSCs移植治疗SLE的效果可能通过抑制CCL2表达,进而下调患者Th17细胞水平来实现。     

不同起搏模式对病窦综合征患者血浆脑钠肽的影响

[目的]探讨心脏起搏器不同起搏模式对病态窦房结综合征（病窦综合征）患者血浆脑钠肽（BNP）水平的影响.[方法]常规植入起搏器的病窦综合征患者30例,根据不同起搏模式分为心房起搏组[AAI（R）组] 12例和双腔起搏组[DDD（R）组] 18例;分别于术前、术后3个月、术后6个月测定血浆BNP水平.[结果]术后3个月时两组血浆BNP水平均升高,但差异无显著性[（113.8±31.3） pg/mLvs （95.7±53.2） pg/mL,（92.8±87.2） pg/mL vs （70.1 74.6±69.3） pg/mL;均P〉0.05];6个月时AAI（R）组血浆BNP水平与3个月时[（84.8±73.7）pg/mL vs （113.8±31.3 ）pg/mL]比较无升高,而DDD（R）组血浆BNP水平较3个月时进一步升高[（98.8±61.7）pg/mL vs （92.8±87.2 ）pg/mL],但差异仍无统计学意义（P〉0.05）.[结论]病窦综合征患者采用心房起搏AAI（R）和双腔起搏DDD（R）两种工作模式血浆BNP水平虽无明显改变,但长期双腔起搏模式下的右心室心尖部起搏可能有导致血浆BNP水平增高的趋势.     

荧光定量聚合酶链反应法检测咽拭子EBV—DNA在早期诊断EBV感染中的作用

目的 探讨咽拭子荧光定量聚合酶链反应（FQ-PCR）法检测非洲淋巴细胞瘤病毒脱氧核糖核（EBV—DNA）在早期诊断EBV感染中的应用价值。方法对于疑诊EBV感染的患儿在疾病初期分别采用咽拭子PCR法检测EBV—DNA,同时用酶联免疫吸附测定（ELISA）法检测静脉血EBV—VCA—IgM和（或）IgG,对于前者阳性而后者阴性的病例在1周后复查EBV—VCAIgM和IgG,比较两者在早期诊断EBV感染中的价值。同期检测健康儿童50例作为对照组。结果①共检测疑诊病例985例,其中EBV—DNA阳性344例,阳性率34．9％,EBV—VCA—IgM和（或）IgG阳性164例,阳性率16．6％;健康对照组检测50例,仅1例EBVDNA阳性,所有病例EBV—VCA—IgM和（或）IgG均阴性。②在纳入研究病例中,诊断为传染性单核细胞增多症者38例,其中EBV—DNA37例阳性、EBV—VCAIgM和（或）IgG27例阳性（P〈0．05）。诊断为非典型EBV感染的312例,其中EBVDNA阳性307例,阳性率98．4％,EBV—VCA—IgM和（或）IgG阳性137例,阳性率43．9％（P〈0．01）。结论咽拭子PCR法检测EBV—DNA敏感度高,特异度强,且取材简单,方法无创,家长易于接受,与检测EBV-VCA—IgM、IgG相比,在早期诊断EBV感染性疾病,尤其是非典型EBV感染很有应用价值。